CLAIMS

1. Use of a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor in manufacture of a medicament for treatment or prevention of constipation;

wherein the DGAT1 inhibitor is trans-4-(4-(5-((6-(trifluoromethyl)pyridin-3-yl)amino)pyridin-2-yl)phenyl)cyclohexane acetic acid (pradigastat) or a pharmaceutically acceptable salt or ester thereof; and

wherein the constipation is opioid-induced constipation, chronic idiopathic constipation, or constipation due to pregnancy, medications, or a neurological disorder.

2. The use according to claim 1, wherein the constipation is chronic idiopathic constipation.

~~3. The use according to claim 1, wherein the constipation is irritable bowel syndrome with constipation.~~

~~4~~3. The use according to claim 1, wherein the constipation is opioid-induced constipation.

~~5. The use according to any one of claims 1 to 4, wherein the DGAT1 inhibitor is a small molecule.~~

~~6. The use according to any one of claims 1 to 4, wherein the DGAT1 inhibitor is trans-4-(4-(5-((6-(trifluoromethyl)pyridin-3-yl)amino)pyridin-2-yl)phenyl)cyclohexane acetic acid (pradigastat) or a pharmaceutically acceptable salt or ester thereof.~~

~~7. The use according to any one of claims 1 to 4, wherein the DGAT1 inhibitor is 3-(4-(6-(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)-1*H*-benzo[*d*]imidazol-2-yl)-3,5-dimethylphenyl)-2,2-dimethylpropanoic acid (compound 9) or a pharmaceutically acceptable salt or ester thereof.~~

4. The use according to any one of claims 1 to 3, wherein the medicament is for treatment or prevention in a human.

5. The use according to claim 1, wherein the neurological disorder is autonomic neuropathy, diabetic-related neuropathy, multiple sclerosis, spinal cord injury, or stroke.

~~8. The use according to any one of claims 1 to 4, wherein the DGAT1 inhibitor is an antibody.~~

~~9~~6. Use of a pharmaceutical composition comprising diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor in manufacture of a medicament for treatment or prevention of ~~opioid-induced~~ constipation~~;~~.

~~10. The use according to claim 9,~~ wherein the DGAT1 inhibitor is trans-4-(4-(5-((6-(trifluoromethyl)pyridin-3-yl)amino)pyridin-2-yl)phenyl)cyclohexane acetic acid (pradigastat) or a pharmaceutically acceptable salt or ester thereof; and~~.~~

wherein the constipation is opioid-induced constipation, chronic idiopathic constipation, or constipation due to pregnancy, medications, or a neurological disorder.

~~11. The use according to claim 9, wherein the DGAT1 inhibitor is 3-(4-(6-(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)-1*H*-benzo[*d*]imidazol-2-yl)-3,5-dimethylphenyl)-2,2-dimethylpropanoic acid (compound 9) or a pharmaceutically acceptable salt or ester thereof.~~

~~12. The use according to claim 9, wherein the DGAT1 inhibitor is an antibody.~~

7. The use according to claim 6, wherein the constipation is chronic idiopathic constipation.

8. The use according to claim 6, wherein the constipation is opioid-induced constipation.

9. The use according to any one of claims 6 to 8, wherein the medicament is for treatment or prevention in a human.

10. The use according to claim 6, wherein the neurological disorder is autonomic neuropathy, diabetic-related neuropathy, multiple sclerosis, spinal cord injury, or stroke.